Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.

导出原文传递

翻译打印收藏纠错

作者： Anil A,Joy ^[1] ; Larissa J,Vos ^[2] ; Edith,Pituskin ^[3] ; Sarah F,Cook ^[4] ; Robert R,Bies ^[4] ; Ann,Vlahadamis ^[2] ; Karen,King ^[1] ; Sanraj K,Basi ^[1] ; Judith,Meza-Junco ^[1] ; John R,Mackey ^[1] ; Avalyn,Stanislaus ^[5] ; Vijaya L,Damaraju ^[5] ; Sambasivarao,Damaraju ^[6] ; Michael B,Sawyer ^[7]

作者单位： Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada; Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. ^[1] Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada. ^[2] Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada; Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. ^[3] Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY. ^[4] Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. ^[5] Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. ^[6] Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada; Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. Electronic address: sawyer@ahs.ca. ^[7]

关键词 SNP UGT2B7 escalation genotype toxicity